Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED50 of propofol combined with nalbuphine during painless gastroscopy in overweight patients
ChiCTR2200066602Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalbuphine and propofol in Overweight (3 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Median effective dose (ED50), Dosage of propofol and 1 more. Started Dec 2022; status: recruiting.
02
Drugs
nalbuphinepropofol
03
Conditions
Overweight
Beyond the preview
Go deeper on ChiCTR2200066602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066602.